Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 2
1985 1
1986 5
1987 8
1988 3
1989 3
1990 4
1991 3
1992 20
1993 18
1994 50
1995 16
1996 9
1997 18
1998 14
1999 14
2000 17
2001 13
2002 13
2003 20
2004 19
2005 11
2006 19
2007 17
2008 10
2009 9
2010 9
2011 9
2012 14
2013 17
2014 15
2015 18
2016 15
2017 6
2018 9
2019 8
2020 10
2021 11
2022 7
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

470 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %
The following terms were not found in PubMed: 5Brn
Page 1
Clinical Usefulness of Arbekacin.
Lee JH, Lee CS. Lee JH, et al. Infect Chemother. 2016 Mar;48(1):1-11. doi: 10.3947/ic.2016.48.1.1. Epub 2016 Mar 31. Infect Chemother. 2016. PMID: 27104010 Free PMC article. Review.
Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). ...The microbiologic efficacy rate ranged from 46.2% to 83%. In comparative studies between arbekacin and glycopeptides, arbekacin was similar to ot …
Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). ...The microbiologic e …
Kanamycin and its derivative, arbekacin: significance and impact.
Hotta K, Kondo S. Hotta K, et al. J Antibiot (Tokyo). 2018 Mar;71(4):417-424. doi: 10.1038/s41429-017-0017-8. Epub 2018 Feb 5. J Antibiot (Tokyo). 2018. PMID: 29402999 Review.
On the occasion of the 60th anniversary of the discovery (1957) of kanamycin (KM), a series of research achievements on KM and its semisynthetic derivative Arbekacin (ABK) are outlined. KM was first used clinically in 1958 and was appreciated for its remarkable curing effe …
On the occasion of the 60th anniversary of the discovery (1957) of kanamycin (KM), a series of research achievements on KM and its semisynth …
Arbekacin.
Kobayashi Y, Uchida H, Kawakami Y. Kobayashi Y, et al. Int J Antimicrob Agents. 1995 Jul;5(4):227-30. doi: 10.1016/0924-8579(95)00014-y. Int J Antimicrob Agents. 1995. PMID: 18611673 No abstract available.
Aprosamine Derivatives Active against Multidrug-Resistant Gram-Negative Bacteria.
Otsuka Y, Umemura E, Takamiya Y, Ishibashi T, Hayashi C, Yamada K, Igarashi M, Shibasaki M, Takahashi Y. Otsuka Y, et al. ACS Infect Dis. 2023 Apr 14;9(4):886-898. doi: 10.1021/acsinfecdis.2c00557. Epub 2023 Mar 9. ACS Infect Dis. 2023. PMID: 36893496
All 8'-beta-glycosylated aprosamine derivatives (3a-h) showed excellent antibacterial activity against carbapenem-resistant Enterobacteriaceae and 16S ribosomal RNA methyltransferase-producing multidrug-resistant Gram-negative bacteria compared to the clinical drug, arbekacin …
All 8'-beta-glycosylated aprosamine derivatives (3a-h) showed excellent antibacterial activity against carbapenem-resistant Enterobacteriace …
Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM.
Matsumoto K, Samura M, Tashiro S, Shishido S, Saiki R, Takemura W, Misawa K, Liu X, Enoki Y, Taguchi K. Matsumoto K, et al. Biol Pharm Bull. 2022;45(7):824-833. doi: 10.1248/bpb.b22-00276. Biol Pharm Bull. 2022. PMID: 35786589 Free article.
The target therapeutic ranges of vancomycin, teicoplanin, and arbekacin have been determined, and therapeutic drug monitoring (TDM) is performed in clinical practice. ...
The target therapeutic ranges of vancomycin, teicoplanin, and arbekacin have been determined, and therapeutic drug monitoring (TDM) i …
[Molecular therapies for Duchenne muscular dystrophy].
Takeshima Y. Takeshima Y. No To Hattatsu. 2016 Jul;48(4):241-6. No To Hattatsu. 2016. PMID: 30010301 Review. Japanese.
The clinical effectiveness of gentamicxin and PTC124 has been reported. We have demonstrated the effectiveness of arbekacin-mediated read-through in vitro. We have already begun an investigator initiated clinical trial of nonsense mutation read-through therapy using arb …
The clinical effectiveness of gentamicxin and PTC124 has been reported. We have demonstrated the effectiveness of arbekacin-mediated …
Plasticity of Aminoglycoside Binding to Antibiotic Kinase APH(2″)-Ia.
Caldwell SJ, Berghuis AM. Caldwell SJ, et al. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00202-18. doi: 10.1128/AAC.00202-18. Print 2018 Jul. Antimicrob Agents Chemother. 2018. PMID: 29661878 Free PMC article.
However, if this binding mode is made impossible because of additional substitutions to the standard 4,5- or 4,6-disubstituted aminoglycoside architecture, as in lividomycin A or the N1-substituted aminoglycosides, it is still possible for these aminoglycosides to bind to the ant …
However, if this binding mode is made impossible because of additional substitutions to the standard 4,5- or 4,6-disubstituted aminoglycosid …
Synthesis of 5-deoxy-5-epifluoro derivatives of arbekacin, amikacin, and 1-N-[(S)-4-amino-2-hydroxybutanoyl]tobramycin (study on structure--toxicity relationships).
Shitara T, Umemura E, Tsuchiya T, Matsuno T. Shitara T, et al. Carbohydr Res. 1995 Oct 16;276(1):75-89. doi: 10.1016/0008-6215(95)00123-b. Carbohydr Res. 1995. PMID: 8536259
The acute toxicities of these three 5-deoxy-5-epifluoro compounds showed values almost identical or similar to those for arbekacin (ABK) and amikacin (15), making a sharp contrast with the toxicities of the corresponding 5-deoxy-5-fluoro derivatives. ...
The acute toxicities of these three 5-deoxy-5-epifluoro compounds showed values almost identical or similar to those for arbekacin (A …
[Nonsense readthrough therapy for Duchenne muscular dystrophy].
Takeshima Y. Takeshima Y. Rinsho Shinkeigaku. 2014;54(12):1074-6. doi: 10.5692/clinicalneurol.54.1074. Rinsho Shinkeigaku. 2014. PMID: 25672712 Review. Japanese.
Clinical effectiveness of gentamicin and PTC124 have been suggested. We have demonstrated that arbekacin-mediated readthrough can substantially ameliorate muscular dystrophy. We already have begun the clinical trial of the nonsense mutation readthrough therapy using arb …
Clinical effectiveness of gentamicin and PTC124 have been suggested. We have demonstrated that arbekacin-mediated readthrough can sub …
The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study.
Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. Hwang JH, et al. Infect Chemother. 2013 Mar;45(1):62-8. doi: 10.3947/ic.2013.45.1.62. Epub 2013 Mar 29. Infect Chemother. 2013. PMID: 24265951 Free PMC article.
We studied the clinical and bacteriological efficacy and safety of arbekacin compared to vancomycin in the treatment of infections caused by MRSA. ...The complication rate was significantly higher in the vancomycin group [29/59(49.2%), 95% CI 35.9 to 62.5%] than arbekac …
We studied the clinical and bacteriological efficacy and safety of arbekacin compared to vancomycin in the treatment of infections ca …
470 results